[HTML] mdpi.com

[HTML][HTML] Sustained and long-term release of doxorubicin from PLGA nanoparticles for eliciting anti-tumor immune responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon, J Kim… - Pharmaceutics, 2022 - mdpi.com
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …
被引用次数：28 相关文章

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - …, 2022 - europepmc.org
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …
[PDF] semanticscholar.org

[PDF][PDF] Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses. Pharmaceutics 2022, 14, 474

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon, J Kim… - 2022 - pdfs.semanticscholar.org
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon, J Kim… - Pharmaceutics, 2022 - cir.nii.ac.jp
抄録< jats: p> Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune
responses against tumors. However, traditional chemoimmunotherapy (CIT) does not last …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - Pharmaceutics …, 2022 - jglobal.jst.go.jp
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting
Anti-Tumor Immune Responses | Article Information | J-GLOBAL Art J-GLOBAL ID:202302226612601895 …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - …, 2022 - search.proquest.com
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - …, 2022 - pure.ewha.ac.kr
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - …, 2022 - search.ebscohost.com
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses

J Kim, Y Choi, S Yang, J Lee, J Choi, Y Moon… - …, 2022 - scholar.korea.ac.kr
Immunogenic cell death (ICD) is a powerful trigger eliciting strong immune responses
against tumors. However, traditional chemoimmunotherapy (CIT) does not last long enough …